TABLE 1.

Comparison of the baseline predictions and the experimental measurements of VEGF, FGF2, TSP1, PF4, and MMPs.

Species	Range of experimental measurements†	Predicted concentration	Source and references
VEGF unbound	8.0 – 389 pM	180.2 pM	Multiple (Finley and Popel, 2013)
TSP1 total ‡	1.0 – 6.2 nM (2.0)	3.0 nM	Breast cancer patient (Byrne et al., 2007)
PF4 unbound	1.0 – 11.3 nM	4.7 nM	Multiple (Leitzel et al., 1991; Kurimoto et al., 1995; Peterson et al., 2012; Sabrkhany et al., 2017)
FGF2 total	0.2 – 11.1 nM	3.9 nM	Prostate cancer patient (Giri et al., 1999)
MMP3 total	1.8 – 65.1 nM (5.1)	5.0 nM	Oral squamous cell carcinoma patient (Baker et al., 2006)
MMP9 total	1.0 – 287.8 nM (9.0)	9.2 nM	Oral squamous cell carcinoma patient (Baker et al., 2006)
MMP9 active	0 – 22.4 nM (0.8)	0.2 nM	Oral squamous cell carcinoma patient (Baker et al., 2006)

^†Median value is shown in parentheses, if provided in literature. If the experimental data reflects the total concentration in tissue, we assume 50% of the total protein amount is in the extracellular space. ^‡TSP1 concentration includes both active TSP1 and cleaved TSP1.